The Hebrew University of Jerusalem is home for more than 3,000 ongoing research projects, 1,200 researchers, 1,400 registered patents, and 5 Nobel laureates that are supported by the Center for Nanoscience and Nanotechnology. Because of this, the Yissum Research and Developmental Company was established in 1964 to encourage and enhance more the “inventiveness” of the Hebrew University of Jerusalem. The Hebrew University of Jerusalem is in the world’s top fifteen academic institutions as measured by revenues coming from intellectual property fees.

Yissum Research and Developmental Company serves as the Technology Transfer Services for the university. Yissum is responsible on the ongoing assessment, protection and commercial optimization of Hebrew University of Jerusalem’s intellectual property. Yissum’s annual revenues were reported around $40 million. The large percentage of their revenue comes from royalty fees.

Serving as the Technology Transfer University for Hebrew University of Jerusalem, they also made partnership with researchers and worldwide businesses to develop more commercial markets and through licensing, establishing companies, and or enhance the market value and performance of inventions made by Hebrew University of Jerusalem. These partnerships help the Hebrew University of Jerusalem to increase their invention’s availability to the global marketplace. It was also reported that the Yissum Research and Developmental Company receives an annual budget amounting to $77 million.

Hebrew University of Jerusalem recently focuses more on the medical arena; their concept is to use cellular technology to send X-rays and other medical diagnostics. This innovation allows the use of a smaller, less expensive and easier to use Data Acquisition Device, which is also known as DAD at remote patient sites. This would bring advanced medical technology into areas, which can’t afford much expensive medical technology. This would really help the medical industry as bringing MRIs and X-rays into rural places are not practical.

Yissums Research and Developmental Company’s list of products and companies is very vast and full of recognized names on the medical and technology field. Their products ranges from Alzheimer and dementia treatment Exelon, dry-eye treatments Cationorm and LO2A (Lacrycon, Dropyal), ovarian cancer treatment Doxil (Caeylx), UV-protection product UV-Pearls—already adopted by major companies for sunscreens and cosmetics, and a variety of other pharmaceutical products. And the long list goes on. Who would forget the long shell life tomatoes?

In the end, Yissum serves the Hebrew University of Jerusalem by protecting intellectual properties and encouraging the researchers to move forward with innovations and technologies, which would benefit, by the whole world.